The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of liposome encapsulated doxorubicin citrate (LEDC) as a valid drug in patients affected by ovarian cancer suffering from chemotherapy side-effects.
Michela Angelucci
No relevant relationships to disclose
Francesco Plotti
No relevant relationships to disclose
Ludovico Muzii
No relevant relationships to disclose
Corrado Terranova
No relevant relationships to disclose
Carlo De Cicco Nardone
No relevant relationships to disclose
Roberto Montera
No relevant relationships to disclose
Patrizio Damiani
No relevant relationships to disclose
Ester Valentina CafĂ 
No relevant relationships to disclose
Nella Dugo
No relevant relationships to disclose
Federica Guzzo
No relevant relationships to disclose
Roberto Ricciardi
No relevant relationships to disclose
Alessia Aloisi
No relevant relationships to disclose
Daniela Luvero
No relevant relationships to disclose
Andrea Miranda
No relevant relationships to disclose
Stella Capriglione
No relevant relationships to disclose
Salvatore Lopez
No relevant relationships to disclose
Giuseppe Scaletta
No relevant relationships to disclose
Francesca Linciano
No relevant relationships to disclose
Pierluigi Benedetti Panici
No relevant relationships to disclose
Roberto Angioli
No relevant relationships to disclose